Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$0.70 -0.05 (-7.27%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$0.69 -0.01 (-1.35%)
As of 04/4/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$0.67
$0.73
50-Day Range
$0.70
$1.84
52-Week Range
$0.67
$3.09
Volume
292,135 shs
Average Volume
101,493 shs
Market Capitalization
$87.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.42
Consensus Rating
Hold

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Remove Ads

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 50% of companies evaluated by MarketBeat, and ranked 489th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Nautilus Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    0.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently increased by 20.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently increased by 20.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nautilus Biotechnology has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,767.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nautilus Biotechnology's insider trading history.
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

NAUT Stock Analysis - Frequently Asked Questions

Nautilus Biotechnology's stock was trading at $1.68 on January 1st, 2025. Since then, NAUT stock has decreased by 58.5% and is now trading at $0.6964.
View the best growth stocks for 2025 here
.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its quarterly earnings data on Tuesday, October, 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

Last Earnings
10/29/2024
Today
4/05/2025
Next Earnings (Estimated)
4/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.42
High Stock Price Target
$3.00
Low Stock Price Target
$1.75
Potential Upside/Downside
+247.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
0.33

Miscellaneous

Free Float
74,711,000
Market Cap
$87.85 million
Optionable
Optionable
Beta
1.25
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:NAUT) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners